Ionis Pharmaceuticals, Inc.
IONS
$75.83
$0.450.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 47.53% | 33.83% | 20.41% | 16.05% | -7.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.53% | 33.83% | 20.41% | 16.05% | -7.64% |
| Cost of Revenue | 4.88% | 2.06% | -3.23% | -2.80% | -2.96% |
| Gross Profit | 163.81% | 105.87% | 161.44% | 147.11% | -21.43% |
| SG&A Expenses | 60.77% | 47.25% | 52.67% | 32.62% | 32.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.56% | 12.30% | 7.94% | 4.50% | 3.84% |
| Operating Income | 25.44% | 19.66% | 20.64% | 22.75% | -28.00% |
| Income Before Tax | 29.96% | 17.49% | 27.28% | 22.15% | -27.60% |
| Income Tax Expenses | 130.81% | 128.95% | -179.00% | -146.95% | -129.17% |
| Earnings from Continuing Operations | 28.61% | 15.97% | 28.56% | 26.67% | -19.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.61% | 15.97% | 28.56% | 26.67% | -19.04% |
| EBIT | 25.44% | 19.66% | 20.64% | 22.75% | -28.00% |
| EBITDA | 26.52% | 20.27% | 21.05% | 23.22% | -29.36% |
| EPS Basic | 32.82% | 22.06% | 33.96% | 30.58% | -11.81% |
| Normalized Basic EPS | 29.23% | 24.20% | 26.65% | 27.11% | -24.58% |
| EPS Diluted | 30.26% | 19.54% | 30.83% | 27.55% | -11.81% |
| Normalized Diluted EPS | 25.42% | 20.50% | 21.68% | 22.12% | -24.58% |
| Average Basic Shares Outstanding | 5.64% | 6.95% | 8.83% | 7.89% | 6.13% |
| Average Diluted Shares Outstanding | 9.44% | 10.82% | 12.80% | 11.89% | 6.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |